Research-grade compound. Laboratory use only. Not intended for human or animal use, ingestion, or injection. No medical claims are made or implied.
≥98% PurityIn-House HPLC & MS Tested
Peptide BlendsSKU: CP-RC10
Retatrutide + Cagrilintide Blend 10mg
≥99% PurityHPLC & MS verified
€44.99Out of Stock
Delivers to EU in 7-10 business days
Free shipping over €200 · no customs paperwork (EU) · via EU carrier network
Research-grade Retatrutide + Cagrilintide Blend. 99.3% avg purity, HPLC & MS verified. Lyophilized powder in sealed glass vial. For laboratory research use only. Not for human consumption.
📦
MADE TO ORDER — Expected delivery: ~3 weeks
Synthesized after your order is placed. We'll email you tracking details when it ships.
Currently Unavailable61 researchers waiting
This product is being restocked
We're working with our supplier to restock this item. Sign up below to be the first to know, or save it to your wishlist.
Important Notice
This product is intended for laboratory and research use only. Not for human or veterinary use. By purchasing, you confirm this product will be used exclusively for in-vitro research purposes.
When This Product May Not Suit Your Research
- ⚠If your research requires GMP-grade material for clinical applications — research-grade peptides are not intended for clinical use.
- ⚠If your lab lacks proper cold storage (-20°C freezer) — this peptide's stability may be compromised at higher temperatures.
- ⚠If your study protocol requires FDA-approved reference standards — contact USP or a certified reference material provider.
Purity HPLC
99.3% average HPLC purity, verified by independent third-party testing
Third-Party Tested
Janoshik report published when available
Fast Shipping
24h dispatch, EU-wide shipping from €4.99
Third-Party Tested
Independent lab verification for every batch
Last reviewed: 2026-04-24
About Retatrutide + Cagrilintide Blend 10mg
Retatrutide + Cagrilintide Blend combines two of the most potent weight management research peptides in clinical development. Retatrutide is a triple agonist (GLP-1/GIP/glucagon receptors) developed by the drug sponsor; Cagrilintide is a long-acting amylin analogue developed by Novo Nordisk. Each vial contains 5mg of each peptide (10mg total). This blend targets metabolic regulation through two distinct but complementary hormonal systems -- gut incretins versus pancreatic amylin.
Retatrutide's triple agonism is its defining characteristic. GLP-1 receptor activation drives satiety and insulin secretion; GIP receptor activation enhances insulin sensitivity and may contribute to lipid metabolism; glucagon receptor activation increases energy expenditure. Phase II trial data showed weight reduction of approximately 17% over 24 weeks at higher doses, making it one of the most potent single agents studied for weight management. As a research compound, it allows study of triple incretin receptor biology and its metabolic consequences.
Cagrilintide mimics amylin, a hormone co-secreted with insulin from pancreatic beta cells. Amylin slows gastric emptying, reduces postprandial glucagon, and has central satiety effects distinct from GLP-1 signaling. Cagrilintide's long half-life (approximately 7 days) enables once-weekly dosing in clinical research. Phase II data from Novo Nordisk showed it produced approximately 8% weight reduction as monotherapy, with combination data with semaglutide (CagriSema) showing stronger effects than either alone.
Specifications
| Parameter | Value |
|---|---|
| Component 1 | Retatrutide 5mg (GLP-1/GIP/glucagon triple agonist) |
| Component 2 | Cagrilintide 5mg (long-acting amylin analogue) |
| Total per Vial | 10mg combined |
| Purity | 99.3% avg HPLC (each component) |
| Format | Lyophilized powder, single-use vial |
| Storage | -20°C before reconstitution; 2-8°C after |
Storage
Store at -20°C before reconstitution. Refrigerate at 2-8°C after reconstitution. Use within 28 days of reconstitution. Both peptides are stable under proper storage conditions.
Why combine a triple incretin agonist with an amylin analogue?
Retatrutide targets the incretin system (GLP-1, GIP, glucagon receptors) while Cagrilintide targets amylin receptor signaling -- two distinct hormonal pathways that independently regulate appetite, satiety, and metabolism. They produce complementary effects through different mechanisms: Retatrutide modulates incretin-driven insulin secretion and energy expenditure; Cagrilintide addresses postprandial satiety and gastric emptying through amylin-mediated pathways. The clinical hypothesis, supported by CagriSema combination data, is that addressing multiple weight regulatory systems simultaneously produces more durable and greater weight reduction than single-pathway approaches.
What is Retatrutide's status in clinical development?
Retatrutide (LY3437943) is in active Phase III clinical development by the drug sponsor for obesity and type 2 diabetes. Phase II data published in 2023 showed approximately 17% body weight reduction at 24 weeks in people with obesity, with dose-dependent effects and a profile consistent with the triple agonism mechanism. It has not yet received regulatory approval but is among the leading next-generation obesity candidates. As a research compound, it allows preclinical and mechanistic study of GLP-1/GIP/glucagon co-agonism.
What makes Cagrilintide different from native amylin?
Native amylin has a very short half-life and propensity for aggregation (amyloid formation), which limits its use as a therapeutic. Cagrilintide is a long-acting amylin analogue engineered for stability and extended duration -- approximately 7-day half-life enabling once-weekly dosing. It retains amylin's core biological actions: slowing gastric emptying, reducing postprandial glucagon, and activating central satiety pathways through amylin receptors in the hypothalamus and area postrema. These properties are complementary to GLP-1 receptor agonism and are why the combination approach is being studied.
Retatrutide + Cagrilintide Blend is supplied for laboratory research use only. Not approved for human use. Handle in compliance with institutional biosafety guidelines.
Specification Summary
Purity99.3% avg
FormLyophilized Powder
Storage-20\u00B0C
Researcher Confidence
Why researchers choose CertaPeptides
Who actually tests this?
Every batch is independently verified by Janoshik Analytical (100,000+ verifications/month), Eurofins Scientific, and Analytical Sciences International. We publish every Certificate of Analysis.
View COAs →What if I get the wrong batch?
Every bottle label carries a lot number that maps to a specific Certificate of Analysis. If a batch fails spec, we don't ship it — full stop.
View COAs →Where does it ship from?
Romania (EU). We are CERTALAB SRL, CUI RO54451735, VAT-registered. SameDay for Romania, FanCourier for Central/Eastern EU, TCE Worldwide for the rest. 3–7 business days EU-wide.
Shipping details →What if there's a problem?
You have a 14-day withdrawal right under OUG 34/2014 (Romanian/EU consumer law), with ANPC/ODR escalation available. Contact us at support@certapeptides.com.
Returns policy →Product Information
This product is intended for scientific research and development purposes only. It is a chemical substance that shall not be used as a drug, medicine, active substance, or ingredient in any product intended for human or animal consumption. Researchers must handle this compound in accordance with their institutional biosafety guidelines. Use only in properly equipped laboratory settings with appropriate personal protective equipment.
Frequently Asked
Research Library
Related Research Articles
Based on category & popularity
Researchers Also Studied
80mgSAME FIELDPeptide Blends
Klow Blend (BPC-157 + GHK-Cu + TB-500 + KPV) 80mg
Research-grade Klow Blend (BPC-157 + GHK-Cu + TB-500 + KPV). 99.3% avg purity, HPLC & MS verified. Lyophilized powder in sealed glass vial. For laboratory research use only. Not for human consumption.
€79.99
18mgSAME FIELDPeptide Blends
Tesamorelin + Ipamorelin Blend 18mg
Research-grade Tesamorelin + Ipamorelin Blend. 99.3% avg purity, HPLC & MS verified. Lyophilized powder in sealed glass vial. For laboratory research use only. Not for human consumption.
€60.99
20mgSAME FIELDPeptide Blends
Semax + Selank Blend 20mg
Research-grade Semax + Selank Blend. 99.3% avg purity, HPLC & MS verified. Lyophilized powder in sealed glass vial. For laboratory research use only. Not for human consumption.
€32.99
70mgSAME FIELDPeptide Blends
Glow Blend (BPC-157 + GHK-Cu + TB-500) 70mg
Three-peptide co-lyophilized research blend: BPC-157 + GHK-Cu + TB-500 in a single 70mg vial. Targets angiogenesis, cell migration, and extracellular matrix renewal simultaneously. 99.3% avg purity (HPLC verified). COA included. For research purposes only. Not for human consumption.
€84.99